Varenicline

Varenicline has been studied in 38 papers since 2014: 7 trials and 12 observational studies in people, 2 in animals, 16 reviews; 30 in the past year. It is an approved medicine. The newest paper, Nov 13, 2026: “Medication-Wide Discovery of Candidate Medications Associated with Alzheimer’s Disease and Related Dementias Using Explainable Artificial Intelligence and Longitudinal Real-World Data”.

InterventionApproved 2006

38 papers study it4 more mention it29 findingsUpdated

PubChemChEBIMeSH

9 new papers in 30 daysSee all 42 papers on varenicline

At a glance

A human preprint associates varenicline with lower risks of Alzheimer’s disease and related dementias, and of these dementias or death, versus nicotine replacement therapy during smoking cessation. A review describes improved combustible tobacco abstinence.

29 findings in 18 papers from 2018 to 2026, 10 of them since April 2026

Independent labs found the same change in mice and people. 12 independent labs in 10 countries; 168 trials, none about aging, 41 with no results posted.

“Individuals with the ST profile responded better to varenicline than to NRT.”
Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trialAddiction (Abingdon, England)2026doi:10.1111/add.70354

None of its findings points the other way.

Mice and humans: replicated by independent labs. Cells and worms or flies: nothing yet.
  • 12 independent labs in 10 countries
  • 168 trials, none about aging, 41 with no results posted
  • Funders: The University of Hong Kong and others
  • 2 of 24 findings with company ties
  • 59 of 168 trials sponsored by its developers
  • Human trial7
  • Humans12
  • Animals2

Studies in people

1 study gave varenicline to people and measured what changed.

What changedDesignPeopleSource

up: Improves smoking abstinence35% Absolute Risk Difference (ARD) favoring varenicline over NRT (absolute cessation rates: 47% and 11%, respectively)

Randomized trialTwelve weeks158 people18-75 yearsGeneral population; Sign-trackers (ST)Addiction (Abingdon, England), Feb 20, 2026

What did studies of varenicline find?

13

Studies of varenicline measured 13 outcomes; the most studied are smoking cessation (4 studies) and cognitive function (2).

Smoking cessation

upin humans3upin reviews1OR 1.88

4 studies
  1. Varenicline is linked with higher smoking cessation in humans (OR = 1.88, 95%CI 1.19-2.98).

    “varenicline (OR = 1.88, 95%CI 1.19-2.98), or heated tobacco products (OR = 2.33, 95%CI 1.01-5.35) had significantly higher odds of quitting successfully”

    Humansn = 5,593

    Moderation of the real-world effectiveness of smoking cessation aids by mental health conditions: A population study

    PLOS mental health

  2. Varenicline improves smoking cessation in type 2 diabetes.

    “varenicline is the only medication that can be strongly recommended”

    Reviewin type 2 diabetes

    International consensus recommendations for smoking cessation in type 2 diabetes from the DiaSmokeFree Working group

    Diabetes research and clinical practice

  3. Varenicline improves smoking cessation in humans (women who smoke).

    “prioritize varenicline for women who smoke due to its proven superior efficacy in women.”

    Reviewwomen who smokefemales

    Smoking cessation in women: taking action with the Capability Approach

    La Presse Médicale Formation

  4. Varenicline improves smoking cessation (first-line pharmacotherapy).

    “Varenicline and combination nicotine replacement therapy continue to demonstrate the highest efficacy among first-line agents.”

    Reviewfirst-line pharmacotherapy

    Emerging and Established Pharmacotherapies for Smoking Cessation: A Review

    Cardiology in review

Cognitive function

upin mice2

2 studies
  1. Varenicline improves cognitive function in aged mice subjected to laparotomy.

    “After chronic varenicline administration (1 mg/kg/day), cognitive dysfunction, hippocampal oxidative stress, as well as fragile mitophagy were improved.”

    Animalsin aged mice subjected to laparotomychronic administrationbrain1 mg/kg/daymales

    Varenicline improved laparotomy-induced cognitive impairment by restoring mitophagy in aged mice

    European journal of pharmacology

  2. Varenicline improves cognitive function in mice after laparotomy.

    “Perioperative varenicline attenuated the cognitive decline and associated tau protein mislocalization”

    Animalsafter laparotomy1 mg/kg/dayperioperativemales

    Varenicline reduces DNA damage, tau mislocalization and post surgical cognitive impairment in aged mice

    Neuropharmacology

Medication adherence

no changein humans1

1 study
  1. Varenicline was not clearly linked with medication adherence in humans (Compared with brand-name varenicline).

    “Medication adherence declined over time in both groups and was comparable throughout follow-up (all P > 0.05).”

    HumansCompared with brand-name vareniclinegeneric24 weeks

    Comparative effectiveness and safety of generic versus brand-name Varenicline for smoking cessation in Chinese population: findings from China National Tobacco Cessation Cohort Study (CNTCCS)

    Drug and alcohol dependence

Biochemically validated 7-day point prevalence abstinence

no changein humans1

1 study
  1. Varenicline was not clearly linked with biochemically validated 7-day point prevalence abstinence in humans (Compared with brand-name varenicline after matching) (33.2% vs. 33.2% after matching; 33.2% vs. 33.8% before matching).

    “At 24 weeks, validated abstinence rates were similar between generic and brand-name varenicline both before matching (33.2% vs. 33.8%) and after matching (33.2% vs. 33.2%).”

    HumansCompared with brand-name varenicline after matchinggeneric24 weeksn = 512

    Comparative effectiveness and safety of generic versus brand-name Varenicline for smoking cessation in Chinese population: findings from China National Tobacco Cessation Cohort Study (CNTCCS)

    Drug and alcohol dependence

Tobacco abstinence

upin humans1

1 study
  1. Varenicline improves tobacco abstinence in humans (for combustible tobacco cessation).

    “varenicline recommended over monotherapy with other agents”

    Reviewfor combustible tobacco cessation

    Tobacco Use Treatment: Synopsis of the 2026 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline

    Annals of internal medicine

Smoking abstinence

upin humans1

1 study
  1. Varenicline improves smoking abstinence in humans (Sign-trackers (ST)) (35% Absolute Risk Difference (ARD) favoring varenicline over NRT (absolute cessation rates: 47% and 11%, respectively)).

    “Individuals with the ST profile responded better to varenicline than to NRT.”

    Human trialSign-trackers (ST)Twelve weeksn = 158

    Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial

    Addiction (Abingdon, England)

Long-term smoking abstinence

upin humans1

1 study
  1. Varenicline increases long-term smoking abstinence in humans (severe mental illness; compared with placebo or minimal care) (10 more per 100 achieving long-term smoking abstinence, 95% CI 5 to 16).

    “Varenicline, bupropion, and nicotine replacement therapy likely improved smoking abstinence in people with severe mental illness compared with placebo or minimal care”

    Reviewsevere mental illness; compared with placebo or minimal care

    Smoking cessation for people with severe mental illness: systematic review and network meta-analysis

    BMJ medicine

Smoking behavior

downin humans1

1 study
  1. Varenicline decreases smoking behavior in humans.

    “Other studies highlighted the significant impact of varenicline on reducing smoking behavior and urges.”

    Review

    Electronic Cigarettes Versus Varenicline for Smoking Cessation: A Systematic Review and Meta-analysis of in-person Support Augmentation Strategies

    Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine

Mitophagy

upin mice1

1 study
  1. Varenicline improves mitophagy in aged mice subjected to laparotomy.

    “After chronic varenicline administration (1 mg/kg/day), cognitive dysfunction, hippocampal oxidative stress, as well as fragile mitophagy were improved.”

    Animalsin aged mice subjected to laparotomychronic administrationhippocampus1 mg/kg/daymales

    Varenicline improved laparotomy-induced cognitive impairment by restoring mitophagy in aged mice

    European journal of pharmacology

More on Mitophagy

Oxidative stress and ROS signaling

downin mice1

1 study
  1. Varenicline decreases oxidative stress and ROS signaling in aged mice subjected to laparotomy.

    “After chronic varenicline administration (1 mg/kg/day), cognitive dysfunction, hippocampal oxidative stress, as well as fragile mitophagy were improved.”

    Animalsin aged mice subjected to laparotomychronic administrationhippocampus1 mg/kg/daymales

    Varenicline improved laparotomy-induced cognitive impairment by restoring mitophagy in aged mice

    European journal of pharmacology

More on Oxidative stress and ROS signaling

All 13

What is varenicline linked with?

9

Studies link varenicline with 9 measures, among them major adverse cardiovascular events, Alzheimer's disease and related dementias and Alzheimer's disease and related dementias risk.

Major adverse cardiovascular events

downin humans2HR 0.57

2 studies
  1. Varenicline is associated with major adverse cardiovascular events in humans (Nicotine or tobacco dependence; compared with no varenicline use) (HR 0.57; 95% CI 0.55-0.59).

    “varenicline was associated with lower risk of MACE (HR 0.57; 95% CI 0.55-0.59)”

    HumansNicotine or tobacco dependence; compared with no varenicline use3 yearsn = 128,359

    Association of Major Adverse Cardiovascular Events with Varenicline versus Bupropion

    AHA Scientific Sessions 2026 abstract

  2. Varenicline is associated with major adverse cardiovascular events in humans.

    “Both varenicline and bupropion individually showed lower mortality and MACE.”

    HumansAfter acute coronary syndrome; added to nicotine replacement therapy versus nicotine replacement therapy alone

    Addition of Bupropion or Varenicline to Nicotine Replacement Therapy After Acute Coronary Syndrome: A Propensity-Matched Real-World Analysis

    AHA Scientific Sessions 2026 abstract

Alzheimer's disease and related dementias

downin humans1downin silico1HR 0.516

2 studies
  1. Varenicline is linked with a lower risk of Alzheimer's disease and related dementias in humans (receiving smoking cessation therapy relative to nicotine replacement therapy) (HR 0.516, 95% CI: 0.353-0.754).

    “Varenicline use was associated with a reduced risk of ADRD (HR 0.516, 95% CI: 0.353-0.754)”

    Humansreceiving smoking cessation therapy relative to nicotine replacement therapy

    Varenicline as a Repurposable Drug Candidate for ADRD Prevention

    medRxiv : the preprint server for health sciencesPreprint

  2. Varenicline is associated with Alzheimer's disease and related dementias in silico.

    “Our analyses yielded both suspected candidates, such as varenicline, which has supportive preclinical and early clinical evidence in ADRD, and novel candidates, such as metolazone”

    In silico

    Hybrid Value-Aware Transformer Identifies Novel and Suspected Drugs for Alzheimer’s Disease

    GSA 2025 abstract

More on Alzheimer's disease and related dementias

Alzheimer's disease and related dementias risk

downin humans1

1 study
  1. Varenicline is associated with Alzheimer's disease and related dementias risk in humans (model-derived association) (Population-level impact score −0.134 per 280 mg; negative scores in 8341 of 8786 users (95%)).

    “Metolazone and varenicline had the most negative population-level impact scores: −0.196 per 1800 mg and −0.134 per 280 mg cumulative dose unit, respectively”

    Humansmodel-derived association280 mg cumulative dose unitn = 8,786

    Medication-Wide Discovery of Candidate Medications Associated with Alzheimer’s Disease and Related Dementias Using Explainable Artificial Intelligence and Longitudinal Real-World Data

    Medical sciences (Basel, Switzerland)

More on Alzheimer's disease and related dementias risk

Continuous smoking abstinence

upin humans1HR 1.09

1 study
  1. Varenicline is associated with continuous smoking abstinence in humans (Nicotine or tobacco dependence; varenicline compared with bupropion) (HR 1.09; 95% CI 1.02-1.17).

    “and other cardiovascular outcomes, as well as higher continuous abstinence rates (HR 1.09; 95% CI 1.02-1.17).”

    HumansNicotine or tobacco dependence; varenicline compared with bupropion3 yearsn = 118,234

    Association of Major Adverse Cardiovascular Events with Varenicline versus Bupropion

    AHA Scientific Sessions 2026 abstract

Smoking cessation

upin humans1HR 2.32

1 study
  1. Varenicline is associated with smoking cessation in humans (HR 2.32; 95% CI 2.12-2.53).

    “Both therapies increased smoking cessation (varenicline HR 2.32; 95% CI 2.12-2.53; bupropion HR 2.25; 95% CI 2.06-2.45).”

    HumansNicotine or tobacco dependence; compared with no varenicline use; cessation identified by ICD-10 code3 yearsn = 128,359

    Association of Major Adverse Cardiovascular Events with Varenicline versus Bupropion

    AHA Scientific Sessions 2026 abstract

Mortality

downin humans1

1 study
  1. Varenicline is associated with mortality in humans.

    “Both varenicline and bupropion individually showed lower mortality and MACE.”

    HumansAfter acute coronary syndrome; added to nicotine replacement therapy versus nicotine replacement therapy alone

    Addition of Bupropion or Varenicline to Nicotine Replacement Therapy After Acute Coronary Syndrome: A Propensity-Matched Real-World Analysis

    AHA Scientific Sessions 2026 abstract

Nonserious adverse reactions

upin humans1

1 study
  1. Varenicline is associated with nonserious adverse reactions in humans (Compared with brand-name varenicline) (32.4% vs. 12.1% at week 1; 18.0% vs. 7.0% at week 12).

    “adverse reactions were more frequently reported with generic varenicline (32.4% vs. 12.1% at week 1; 18.0% vs. 7.0% at week 12; all P < 0.001)”

    HumansCompared with brand-name vareniclinegenericWeeks 1 and 12

    Comparative effectiveness and safety of generic versus brand-name Varenicline for smoking cessation in Chinese population: findings from China National Tobacco Cessation Cohort Study (CNTCCS)

    Drug and alcohol dependence

Smoking abstinence

upin humans1OR 4.46

1 study
  1. Varenicline is associated with smoking abstinence in humans (OR 4.46, 95% CI 1.51–13.16; p = 0.007).

    “varenicline (OR = 4.46, 95% CI 1.51–13.16, p = 0.007) significantly increased the likelihood of smoking abstinence compared to NRT”

    HumansCompared with nicotine replacement therapy; adjusted for cardiovascular disease history, pack-years, and nicotine dependence12 weeks58% malessn = 169

    Breaking the habit: comparative effectiveness of smoking cessation therapies in a cardiovascular hospital based clinical setting

    ESC Congress 2026 abstract

ADRD or death

downin humans1HR 0.657

1 study
  1. Varenicline is linked with a lower risk of ADRD or death in humans (receiving smoking cessation therapy relative to nicotine replacement therapy) (HR 0.657, 95% CI: 0.501-0.861).

    “and the composite outcome ADRD or death (HR 0.657, 95% CI: 0.501-0.861).”

    Humansreceiving smoking cessation therapy relative to nicotine replacement therapy

    Varenicline as a Repurposable Drug Candidate for ADRD Prevention

    medRxiv : the preprint server for health sciencesPreprint

What acts on varenicline?

1

Studies name nicotine replacement therapy as acting on varenicline.

Nicotine replacement therapy

no changein humans1OR 1.06

1 study
  1. Nicotine replacement therapy showed no clear effect on varenicline in network meta-analysis (OR 1.06, 95% CrI 0.75-1.48).

    “combination nicotine replacement therapy showed no clear difference versus varenicline in network meta-analysis (odds ratio, 1.06; 95% credible interval, 0.75-1.48)”

    Reviewin network meta-analysis

    Smoking cessation policy gaps in South Korea: an MPOWER Framework analysis with AI-assisted multi-source evidence synthesis (2021-2026)

    Korean journal of family medicine

More on Nicotine replacement therapy

Has varenicline been tested in people?

0 of 168 about aging

Yes: 7 trials and 12 observational studies in people have been published, and 159 trials are registered.

Latest change Dry eye disease: Human trials → ApprovedNov 11, 2026

Approved

Repurposing

40 of 53

In trials

  • Cigarette smoking

    Phase 4Results posted11 trials

  • Vaping

    Phase 4Recruiting5 trials

  • Alcohol drinking

    Phase 4Results posted4 trials

  • Cognition disorder

    Phase 4Results posted2 trials

  • Marijuana Abuse

    Phase 4Recruiting2 trials

  • Attention deficit disorder with hyperactivity

    Phase 4Terminated1 trial

All 10

Stopped

  • NCT00907218TerminatedSmoking cessation

    extremely slow enrollment

  • NCT01772641TerminatedTobacco use disorder

    difficulty recruiting and retaining participants

  • NCT04602494TerminatedTobacco use disorder

    The pilot study used apo-varenicline under temp FDA authorization. When varenicline was available an IND exemption was granted to enroll children, IRB approved a trial of varenicline in participants ages 16-25 June 27, 2022, the pilot was terminated

  • NCT02147132TerminatedSmoking

    Difficulty recruiting eligible participants; study medication was expiring.

  • NCT02473562TerminatedParkinson's disease

    insufficient patient enrollment, insufficient funds for completion

  • NCT02856581TerminatedLung neoplasm

    Slow accrual

All 9

Who is developing varenicline?

1 company: Kriya Therapeutics.

Companies
  • Kriya TherapeuticsPhase 1/2trigeminal neuralgia

Trial sponsors

Funding

5 grants since 2018

National Institute of Neurological Disorders and Stroke$2.2MNational Cancer Institute$1.2MUS Department of Veterans Affairs

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 2Jan 2026: 2Feb 2026: 3Mar 2026: 5Apr 2026: 2May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 2Sep 2026: 4Oct 2026: 5Nov 2026: 632 papers in 12 months

See all 42 papers on varenicline